Who are bOPV 1,3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): bOPV (two dose), bOPV (three dose), Arm E: f-IPV and bOPV, M-M-RTM II, Measles-Rubella (MR) Vaccine, Smallpox and Mpox Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bopv-1-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

bOPV 1,3 — Competitive Intelligence Brief

bOPV 1,3 (bOPV 1,3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated viral vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated viral vaccine Poliovirus types 1 and 3 Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

bOPV 1,3 (bOPV 1,3) — Institute of Medical Biology, Chinese Academy of Medical Sciences. bOPV 1,3 is a bivalent oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
bOPV 1,3 TARGET	bOPV 1,3	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Live attenuated viral vaccine	Poliovirus types 1 and 3
bOPV (two dose)	bOPV (two dose)	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus types 1 and 3
bOPV (three dose)	bOPV (three dose)	Centers for Disease Control and Prevention	marketed	vaccine	Poliovirus types 1 and 3
Arm E: f-IPV and bOPV	Arm E: f-IPV and bOPV	Centers for Disease Control and Prevention	phase 3	vaccine	Poliovirus types 1 and 3 antigens
M-M-RTM II	M-M-RTM II	Merck Sharp & Dohme LLC	marketed	Live attenuated viral vaccine
Measles-Rubella (MR) Vaccine	Measles-Rubella (MR) Vaccine	PT Bio Farma	marketed	Live attenuated viral vaccine
Smallpox and Mpox Vaccine	Smallpox and Mpox Vaccine	SIGA Technologies	marketed	Live attenuated viral vaccine / Recombinant viral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated viral vaccine class)

Jean-Pierre Van geertruyden · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Centers for Disease Control and Prevention · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hospital Clinic of Barcelona · 1 drug in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 1 drug in this class
Institute of Tropical Medicine, Belgium · 1 drug in this class
International Vaccine Institute · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bOPV 1,3 — Competitive Intelligence Brief. https://druglandscape.com/ci/bopv-1-3. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab